Additional Coverage:
- The shortage of popular weight loss drug tirzepatide is over, FDA says. Patients could see higher costs as a result. (newsbreak.com)
FDA Ends Tirzepatide Shortage, Impending Crackdown on Compounded Drugs
The FDA has announced that the popular weight loss drug tirzepatide is no longer in shortage, potentially signaling a crackdown on cheaper compounded versions of the medication.
Tirzepatide is the active ingredient in Eli Lilly’s drugs Mounjaro and Zepbound, used to treat diabetes and obesity. These medications have been in high demand, leading to a shortage.
As a result, pharmacies have been offering custom-made versions of tirzepatide at lower costs. However, with the shortage ending, the FDA plans to restrict compounded tirzepatide, affecting patients who rely on the more affordable option.
Concerns for Patients and Telehealth
Patients express concerns about the potential increase in costs and limited access to lower-priced tirzepatide. Telehealth companies that connect patients with weight loss drugs are also adapting to the situation.
Companies Seek Alternatives
Eli Lilly has partnered with telehealth company Ro to offer a lower-cost version of Zepbound in vials to address supply chain issues and compete with compounded drugs. Other pharmaceutical companies and biotech startups are also developing new GLP-1 medications.
Ongoing Challenge
Despite the FDA’s decision, the issue of accessibility and affordability of weight loss drugs remains unresolved. The high cost of brand-name medications may continue to hinder access for many who need them.